

This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Cancer				
Cancer	Spliceosome	<p>Studies in mice and in cell culture have shown that synthetic analogs of FR901464 could help treat cancer. FR901464, a natural product isolated from <i>Pseudomonas</i>, is a spliceosome modulator that induces cell-cycle arrest. In a panel of 23 human cancer cell lines, one of the analogs inhibited proliferation with IC₅₀ values in the nanomolar to single-digit micromolar ranges. In a mouse model of human mantle cell lymphoma, the compound produced dose-dependent reductions in tumor proliferation compared with vehicle ($p < 0.0001$). Next steps include additional animal studies using better formulations of the compounds.</p> <p>SciBX 2(44); doi:10.1038/scibx.2009.1626 Published online Nov. 12, 2009</p>	Patent application filed covering compounds and their use in multiple types of cancer; available for licensing from the St. Jude Children's Research Hospital Office of Technology Licensing	Lagiseti, C. <i>et al. J. Med. Chem.</i> ; published online Oct. 30, 2009; doi:10.1021/jm901215m Contact: Thomas R. Webb, St. Jude Children's Research Hospital, Memphis, Tenn. e-mail: thomas.webb@stjude.org